Is Erdafitinib available in the country?

Erdafitinib (Erdafitinib) is a new type of oral anti-cancer drug that belongs to the category of tyrosine kinase inhibitors. Its main function is to inhibit the activity of fibroblast growth factor receptor (FGFR), thereby blocking the abnormally activated FGFR signaling pathway, thereby inhibiting the growth and spread of cancer cells.

Erdafitinib is not currently available in the country, so patients cannot purchase it domestically and need to purchase erdafitinib through foreign channels. The original drug of erdafitinib is mainly the Hong Kong version of the original drug, with a price of more than 20,000, and needs to be purchased through a Hong Kong pharmacy. The generic drugs are relatively cheaper, mainly the Laos version and the Bangladesh Yaopin International version, with a price of about 1,000 to 2,000, and the ingredients of the original drug and the generic drug are basically the same.

FGFR is a type of receptor involved in cell growth and differentiation, and plays an important regulatory role in normal cells. However, in some cancers, abnormal gene activation of FGFR may occur, leading to excessive proliferation of malignant cells. The design concept of erdafitinib is to achieve the purpose of treating cancer by specifically inhibiting this abnormal activation.

Erdafitinib is primarily used to treat advanced or metastatic urothelial carcinoma with FGFR gene mutations or activation. This type of cancer often responds poorly to traditional treatments, so the emergence of erdafitinib provides a new treatment option for these patients.

Clinical trial results show that erdafitinib shows significant efficacy in some patients, especially when other treatment options are ineffective or inapplicable. In 2019, erdafitinib was approved by the U.S. Food and Drug Administration (FDA) and became an innovative drug for the treatment of specific types of bladder cancer.

Although erdafitinib brings new hope to some cancer patients, like other drugs, it may also cause some adverse reactions, including but not limited to high blood pressure, fatigue, hand-foot syndrome, etc. Patients need to be treated under the supervision of a doctor when using erdafitinib and promptly report any symptoms of discomfort.